FibroGen, AstraZeneca terminate U.S./RoW roxadustat collaboration agreement

FibroGen (FGEN) announced that FibroGen and AstraZeneca (AZN) have agreed to terminate the U.S./RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization rights in the United States and other territories outside of China not licensed to Astellas Pharma (ALPMY). Pursuant to a termination and transition agreement entered into between the parties, AstraZeneca is returning all U.S./RoW roxadustat rights to FibroGen and providing certain assistance during a transition period. FibroGen’s collaboration agreement with AstraZeneca for roxadustat in China remains in place and roxadustat remains the leader in China by brand value share in the chronic kidney disease, or CKD, anemia category. In the event FibroGen subsequently monetizes or commercializes roxadustat in the territories formerly licensed under the U.S./RoW collaboration agreement, FibroGen will have certain financial obligations to AstraZeneca.